{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=15", "query": { "intervention": "Peptide vaccine", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 749, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T22:17:37.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04892043", "title": "Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Tumor" ], "interventions": [ { "name": "SQZ-AAC-HPV", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SQZ Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-08-19", "completion_date": "2023-11-02", "has_results": false, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 6, "location_summary": "Duarte, California • La Jolla, California • Detroit, Michigan + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04892043" }, { "nct_id": "NCT04287868", "title": "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "HPV Cancers", "Anal Cancer", "Oropharyngeal Cancer", "Vulvar, Vaginal, Penile, Rectal Cancer" ], "interventions": [ { "name": "PDS0101", "type": "BIOLOGICAL" }, { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "NHS-IL12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2020-06-09", "completion_date": "2026-05-14", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04287868" }, { "nct_id": "NCT07377435", "title": "DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Refractory Multiple Myeloma", "Relapse Multiple Myeloma" ], "interventions": [ { "name": "DC/MM Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "David Avigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2026-01-30", "completion_date": "2032-03-01", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07377435" }, { "nct_id": "NCT03300817", "title": "MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "MUC1 Peptide-Poly-ICLC Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2017-12-27", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Pittsburgh, Pennsylvania", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300817" }, { "nct_id": "NCT03004248", "title": "Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glabellar Frown Lines" ], "interventions": [ { "name": "Botulinum Toxins, Type A", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Revance Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2691, "start_date": "2016-12-09", "completion_date": "2018-10-17", "has_results": true, "last_update_posted_date": "2022-07-13", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03004248" }, { "nct_id": "NCT00085189", "title": "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Metastatic Intraocular Melanoma", "Mucosal Melanoma", "Recurrent Intraocular Melanoma", "Recurrent Melanoma", "Stage IIC Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIA Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIB Melanoma", "Stage IIIC Intraocular Melanoma", "Stage IIIC Melanoma", "Stage IV Intraocular Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "recombinant MAGE-3.1 antigen", "type": "BIOLOGICAL" }, { "name": "multi-epitope melanoma peptide vaccine", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "agatolimod sodium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 42, "start_date": "2004-05", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085189" }, { "nct_id": "NCT00293423", "title": "GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "HSPPC-96", "type": "BIOLOGICAL" }, { "name": "Standard Surgical Resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2005-11-18", "completion_date": "2013-01-12", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 3, "location_summary": "San Francisco, California • New York, New York • Cleveland, Ohio", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00293423" }, { "nct_id": "NCT01660529", "title": "Multi-peptide Vaccine With Basilixumab for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "hTERT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-06", "completion_date": "2015-11-20", "has_results": false, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660529" }, { "nct_id": "NCT00002637", "title": "Biological Therapy in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gene-modified tumor cell vaccine therapy", "type": "BIOLOGICAL" }, { "name": "recombinant interferon gamma", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "1995-01", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002637" }, { "nct_id": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "PD-L1 Positive", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Advanced Squamous Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-12-22", "completion_date": "2027-12-09", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-14T22:17:37.424Z", "location_count": 5, "location_summary": "Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Roslyn", "state": "New York" }, { "city": "West Islip", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955290" } ] }